Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 17.50 15,500 08:00:00
Bid Price Offer Price High Price Low Price Open Price
17.00 18.00 17.50 17.50 17.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.76 -10.39 -13.49 20
Last Trade Time Trade Type Trade Size Trade Price Currency
15:49:21 O 1,000 17.40 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-16 14:49:2217.401,000174.00O
2019-10-16 13:37:4817.4010,5001,827.00O
2019-10-16 11:27:3917.014,000680.40O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
16/10/2019
09:20
Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 17.50p.
Avacta Group Plc has a 4 week average price of 17.25p and a 12 week average price of 17.25p.
The 1 year high share price is 49p while the 1 year low share price is currently 17.25p.
There are currently 115,956,471 shares in issue and the average daily traded volume is 364,415 shares. The market capitalisation of Avacta Group Plc is £20,292,382.43.
11/10/2019
13:32
chilly0: Suffering is an inevitable outcome for any AIM investor. Either embrace the pain or quit. 50p bid from moderna or any other company would be a steal and in my opinion not good. The only question is does the technology work and can the board commercialize within an acceptable time period. Some investor have been negative re the board but they have done what they said they would do. Obviously this is still a waiting game for a positive outcome but if and when that materialises then these share will rerate quick. I'm not happy where the share price is but investing in lottery ticket companies is not easy
10/10/2019
09:12
74tom: @Babbler, I think the management see the market as a bottomless pit & that if they continue to sign new deals or release exciting data they will always be able to raise more cash. Whilst this has been true to date, the impact of such a strategy on the share price is evident to everyone.
12/9/2019
00:41
danatkins: Tony I think you are a wiser individual. Company has no control over the share price. Biotech have been hit hard the last few years. look at etf labu says it all. the co is in easily stage development with risk attached same as all biotech companies
02/8/2019
19:51
lantanatony: Can anyone please explain how Avacta are going to fund in house clinical trials with a share price of 25pence? Share holders were told 2019 would be most exciting year!.....
01/7/2019
22:33
rubstick: They are going to have to raise money and at this share price that will be expensive. That is the risk of this company and it is quite possible existing holders could be diluted significantly.
01/7/2019
14:42
lantanatony: Bumpa , That's why I feel Avacta should try to raise funds in America. But you need a solid story and good Broker Do Avacta have either? The share price says NO!
07/5/2019
12:41
danatkins: Agree re don't sell and wait it out games being played. Very low volume. If you believe in the tech then hold and add if you feel comfortable. The share price and the tech are not the same. I invested because I believe in the tech not of share price. Weak hands will get flushed out
23/1/2019
19:42
cf456: Poor attempt at a deramp there. Today's volume is low. There has been no heavy selling, just a little bit of profit taking in a strong uptrend. The price has moved up 100% since December and in the past couple of days hit multi-month highs. Quite understandable that some feel tempted to take profits. The fun has barely started here. LG Chem the first of multiple anticipated deals. Looking forward to much greater share price appreciation in the coming months. Fully expect retracements along the way. Nothing moves in a straight line. But the trend is now up and multiples of the current share price over time can be expected.
30/12/2018
15:37
bumpa33: Malcolm Stacey, long time follower of AVCT gives his reasoning for picking them as one of his tips of the year. Nothing we don’t really know already... Between now and January 2nd we shall be publishing more than 20 share tips of the year – buys and sells. Second up is one from Malcolm Stacey. Hello Share Trouncers. Investing in medical pioneers - especially smaller ones - is one of the riskiest ploys you can adopt in Shareland. But the rewards are usually glittering. Probably the best-placed modest pharma in my collection at the mo is Avacta (AVCT). For a long time now the share price has slowly decayed. That’s the fate of many a penny share which hasn’t been able to publish recent good news. However, all that’s changed in the last few weeks. Firstly, let me explain why Avacta has been raising interest in the medical world. It produces affimers. These are alternatives to antibodies. The latter are produced in animals to treat diseases, some of them serious. The advantages of artificial antibodies is that they don't have to be produced in animals, they are more stable and probably cheaper to develop. The market is worth billions and a big South Korean pharma, LG Group, has realised this. It is investing up to £180 million pounds in Avacta. And that’s good because we all know medical research is acutely expensive. On top of this, the deal allows the Wetherby firm to collect royalties. On the heels of this welcome news came tiding that a big new cheese was being appointed from the Swiss giant Roche. He is Doctor Jose Saro, who’ll oversee the affirmer project. And by all accounts this chap really knows how to develop new treatments. These people would not be scrambling onto Avacta’s bandwagon if they had not researched the possibilities throughly. As lay people we cannot make a judgement on the usefulness of affimers. But these heavy-hitters know their stuff and we can probably attach high value to their support. The share price leapt on December’s news. But it’s fallen slightly since. And I really don't think the market has realised the potential - yet.
28/12/2018
10:28
74tom: Disagree that it depends on the markets, unless we have an armageddon event. With a 33m Mcap if the positive news flow continues in 2019 the current share price will increase considerably. Trading is fine but it’s such behaviour that has held the current share price below 33p since the LG deal, as every time we get momentum a rash of 10% profit taking occurs. The simplest rule that allows the price to rise and derisks fully it to sell half when the price doubles, leaving a free carry on the remainder.
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191017 01:03:30